期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

苯达莫司汀治疗肿瘤的临床试验研究进展 被引量：1

原文传递
导出
摘要 盐酸苯达莫司汀是一种含有氮芥基团和苯并咪唑环的双功能氮芥衍生物,其药理作用是通过烷化作用使DNA单链和双链交联,干扰DNA的合成与功能,从而发挥抗肿瘤作用,自上市以来被广泛用于血液系统肿瘤及乳腺癌等实体肿瘤的治疗.2008年美国食品和药物管理局（FDA）批准盐酸苯达莫司汀注射液用于慢性淋巴细胞白血病及惰性B细胞非霍奇金淋巴瘤的治疗.苯达莫司汀作为新一代抗肿瘤药物,对多种恶性肿瘤疗效确切,可明显降低患者的肿瘤复发率与病死率,且不良反应小,安全性高.苯达莫司汀与苯丁酸氮芥、马法兰、环磷酰胺、米托蒽醌及其他蒽环类抗肿瘤药物无交叉耐药性,骨髓抑制呈剂量限制性,非血液学不良反应也很温和.本文对近年来报道的苯达莫司汀单药及联合应用治疗肿瘤的临床试验研究进行综述如下.
作者 王文雯
机构地区 北京中医药大学第三附属医院肿瘤血液科
出处 《中华生物医学工程杂志》 CAS 2013年第5期420-423,共4页 Chinese Journal of Biomedical Engineering
关键词 抗肿瘤作用 苯并咪唑 试验研究 治疗 临床 蒽环类抗肿瘤药物 B细胞非霍奇金淋巴瘤 美国食品和药物管理局
分类号 R73-3 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Schrijvers D, Vermorken JB. Phase I studies with bendamustine: an update. Semin Oncol, 2002, 29(4 Suppl 13) : 15-18. 被引量：1
  • 2Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non- Hodgkin's-lymphomas. J Cancer Res Clin Oncol, 2002, 128 : 603- 609. 被引量：1
  • 3Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non- Hodgkin lymphoma: results from a Multicenter Study. Cancer, 2010, 116: 106-114. 被引量：1
  • 4Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci, 2010, 101 : 2059- 2064. 被引量：1
  • 5Robinson KS, Williams ME, van der Jagt RH, et al. Phase U multieenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol, 2008, 26: 4473-4479. 被引量：1
  • 6Ogura M, Ando K, Taniwaki M, et al. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non- Hodgkin's lymphoma. Cancer Sci, 2011, 102: 1687-1692. 被引量：1
  • 7Weide R, Hess G, Kappler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma, 2007, 48: 1299-1306. 被引量：1
  • 8Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood, 2011, 118 : 3419-3425. 被引量：1
  • 9Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs, 2001, 12: 725-729. 被引量：1
  • 10Knauf WU, Lissichkov T, Aldaoud A, et al. Phase 111 randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol, 2009, 27: 4378-4384. 被引量：1

二级参考文献44

  • 1Knauf WU,Lissichkov T,Aldaoud A,et al.Bendamustin eversus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL):re-sults of an international phase Ⅲ study.Blood (ASH Annual Meeting Abstracts),2007,110:2043. 被引量：1
  • 2Knauf WU,Lissichkov T,Aldaoud A,et al.Phase Ⅲ Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia.J Clin Oncol,2009,27 (26):4378-4384. 被引量：1
  • 3Knauf WU,Lissichkov T,Aldaoud A,et al.Bendamustine in the Treatment of Chronic Lymphocytic Leukemia -Consistent Superiority Over Chlorambucil in Elderly Patients and Across Clinically Defined Risk Groups.Blood (ASH Annual Meeting Abstracts),2009,114:2367. 被引量：1
  • 4Weide R,Pandorf A,Heymanns J,et al.Bendamustine/mitoxantrone/rituxi-mab (BMR):A very effective,well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies Final results of a pilot study.Leuk Lymphoma,2004,45 (12):2445-2449. 被引量：1
  • 5Fischer K,Cramer P,Stilgenbauer S,et al.Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL:A Multicenter Phase Ⅱ Trial of the German CLL Study Group (GCLLSG).Blood (ASH Annual Meeting Abstracts),2009,114:205. 被引量：1
  • 6Kahl B,Bartlett NL,Leonard JP,et al.Bendamustine is effective therapy in patients with rituximab-refractory,indolent B-cell non-Hodgkin lymphoma.results from a Multicenter Study.Cancer,2010,116(1):106-114. 被引量：1
  • 7Michinori O,Toshiki U,Kiyoshi A,et al.Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell NonHodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL):Final Results of a Japanese Multicenter Phase Ⅱ Study.Blood (ASH Annual Meeting Abstracts),2009,114:3694. 被引量：1
  • 8Cephalon Inc.(2008) Treanda (bendamustine hydrochloride for injection) for intravenous infusion:US prescribing information.Cephalon,Inc,Frazer. 被引量：1
  • 9Weide R,Hess G,Koppler H,et al High anti-lymphoma activity of benda-mustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas.A multicenter phase Ⅱ study of the German Low Grade Lymphoma Study Group(GLSG).Leuk Lymphoma,2007,48(7):1299-1306. 被引量：1
  • 10Fowler N,Brad S Kah,Rosen P,et al.Bortezomib,Bendamustine,and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma:Encouraging Activity in the Phase 2 VERTICAL Study,Blood (ASH Annual Meeting Abstracts),2009,114:933. 被引量：1

共引文献10

同被引文献18

  • 1Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classi- fication of lymphoid neoplasms and beyond: evolving concepts and practical applications[J]. Blood, 2011, 117 (19) :5019-5032. 被引量：1
  • 2Lunning MA, Vose JM. Management of indolent lymphoma: where are we now and where are we going[J]. Blood Rev, 2012, 26(6) :279-288. 被引量：1
  • 3Montoto S, FitzgibbonJ. Transformation of indolent B--cell lym- phomas[J].J Clin Oncol, 2011, 29(14):1827-1834. 被引量：1
  • 4Marcus R, Imrie K, Solal-Cefigny P, et al. Phase HI study of R- CVP compared with cyclophosphamide, vincristine, and predni- sone alone in patients with previously untreated advanced follicu- lar lymphoma[J].J Clin Oncol, 2008, 26(28):4579--4586. 被引量：1
  • 5Sousou T, Friedberg j. Rituximab in indolent lymphomas[J]. Semin Hematol, 2010, 47(2):133-142. 被引量：1
  • 6Hoy SM. Bendamusdne: a review of its use in the management of chronic lymphocytic leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple myeloma[J]. Drugs, 2012, 72(14):1929-1950. 被引量：1
  • 7Cheson BD, Homing SJ, Coiffier B, et al. Report of an interna- tional workshop to standardize response criteria for non-Hodg- kin's lymphomas. NCI Sponsored International Working Group [J].J Clin Oncol, 1999, 17(4):1244--1253. 被引量：1
  • 8Leoni LM, Bailey B, ReifertJ, et al. Bendamustine (Treanda) dis- plays a distinct pattern of cytotoxicity and unique mechanistic fea- tures compared with other alkylating agents[J]. Clin Cancer Res, 2008, 14(1):309-317. 被引量：1
  • 9Beeharry N, RattnerJB, Bellacosa A, et al. Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine[J]. PLoS One, 2012, 7(6):e40342. 被引量：1
  • 10Leoni LM, HartleyJA. Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity[j]. Semin Hematol, 2011, 48(1) :S12-$23. 被引量：1

引证文献1

二级引证文献8

中华生物医学工程杂志
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部